Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System

Inspira Technologies (NASDAQ: IINN) is launching the global commercial rollout of its FDA-cleared INSPIRA™ ART100 system following successful clinical implementations in U.S. medical centers. The company is actively engaged in sales discussions with governmental health departments and private organizations, with deliveries expected to begin in H2 2025. The ART100, designed as an alternative to mechanical ventilation, has demonstrated real-world effectiveness in critical care settings. While focusing on ART100 commercialization, Inspira continues developing its innovation pipeline, including the next-generation INSPIRA™ ART500 and HYLA™ blood sensor. The strategic shift aims to capitalize on growing demand for respiratory solutions while prioritizing near-term revenue generation.

https://www.stocktitan.net/news/IINN/inspira-technologies-initiates-global-commercial-rollout-of-fda-s9v4v5d1jhn4.html